Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir
Drug ID BADD_D01905
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status Prescription
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D06676
MeSH ID D000068898
PubChem ID 54671008
TTD Drug ID D0I1FQ
NDC Product Code 65977-0049; 70518-1621; 17381-749; 68071-2113; 0006-3080; 0006-0477; 0006-0473; 0006-0227; 50090-1085; 0006-3603
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H21FN6O5
CAS Registry Number 518048-05-0
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal disorder07.11.01.0010.011331%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Genital herpes21.10.03.008; 11.05.02.012--Not Available
Headache17.14.01.001--
Heart disease congenital03.07.07.001; 02.01.01.0090.001971%Not Available
Hepatic failure09.01.03.0020.002956%
Hepatic function abnormal09.01.02.0010.007554%Not Available
Hepatitis09.01.07.0040.007554%Not Available
Hepatitis acute09.01.07.0050.007554%Not Available
Hepatitis B09.01.09.003; 11.05.06.0020.015108%
Hepatocellular injury09.01.07.0080.033992%Not Available
Hepatomegaly09.01.05.0010.018884%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.037769%Not Available
Herpes zoster11.05.02.003; 23.09.03.002--
HIV infection10.03.03.002; 11.05.17.0020.002956%Not Available
Hydronephrosis20.01.05.0010.011331%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.011331%
Hypersensitivity10.01.03.0030.018884%
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.007554%
Hypoglycaemia neonatal18.04.06.003; 14.06.03.006; 05.06.03.0060.011331%Not Available
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.0020.022661%
Intestinal obstruction07.13.01.0020.011331%Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.001971%Not Available
Ketoacidosis14.01.01.0080.007554%Not Available
Lipoma16.18.01.001; 15.09.01.0010.011331%Not Available
Liver disorder09.01.08.0010.007554%Not Available
Liver function test abnormal13.03.01.0130.007554%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages